With the recent addition of anti-angiogenic agents to cancer treatment, the angiogenesis regulators in platelets are gaining importance. Platelet factor 4 (PF-4/CXCL4) and Connective tissue activating peptide III (CTAP-III) are two platelet-associated chemokines that modulate tumor angiogenesis, inflammation within the tumor microenvironment, and in turn tumor growth. Here, we review the role of PF-4 and CTAP-III in the regulation of tumor angiogenesis; the results of clinical trial using recombinant PF-4 (rPF-4); and the use of PF-4 and CTAP-III as cancer biomarkers.

Department of Laboratory Medicine Masaryk Memorial Cancer Institute Zluty kopec 7 Brno 656 53 Czech Republic

Zobrazit více v PubMed

Klement GL, Yip TT, Cassiola F, Kukuchi L, Cervi D, Podust V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, Almog N, Kieran MW, Folkman J. Platelets actively sequester angiogenesis regulators. Blood. 2009;130:2835–2842. PubMed PMC

Von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost. 2007;97:704–713. PubMed

Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1–8. PubMed

Fivenson DP, Faria DT, Nickoloff BJ, Poverini PJ, Kunkel S, Burdick M, Strieter RM. Chemokine and inflammatory cytokine changes during chronic wound healing. Wound Repair Regen. 1997;5:310–322. doi: 10.1046/j.1524-475X.1997.50405.x. PubMed DOI

Strieter RM, Polverini PJ, Kunkel SL. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995;270:27348–27357. doi: 10.1074/jbc.270.45.27348. PubMed DOI

Deuel TF, Keim PS, Farmer M, Heinrikson RL. Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci USA. 1977;74:2256–2258. doi: 10.1073/pnas.74.6.2256. PubMed DOI PMC

Tunnaclife A, Majumdar S, Yan B, Poncz M. Genes for beta-thromboglobulin and platelet factor 4 are closely linked and form part of a cluster of related genes on chromosome 4. Blood. 1992;79:2896–2900. PubMed

Ryo R, Nakeff A, Huang SS, Ginsberg M, Deuel TF. New synthesis of a platelet-specific protein: platelet factor 4 synthesis in a megakaryocyte-enriched rabbit bone marrow culture system. J Cell Biol. 1983;96:515–520. doi: 10.1083/jcb.96.2.515. PubMed DOI PMC

Barber AJ, Käser-Glanzmann R, Jakábová M, Luscher EF. Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochem Biophys Acta. 1972;286:312–329. doi: 10.1016/0304-4165(72)90267-X. PubMed DOI

Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Fox L, Klement GL, Folkman J. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol. 2010;85:487–493. doi: 10.1002/ajh.21732. PubMed DOI

Zucker B, Katz R. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med. 1991;198:693–702. doi: 10.3181/00379727-198-43309. PubMed DOI

Kaper B, Petersen F. Molecular pathways of platelet factor 4/CXCL4 signaling. Eur J Cell Biol. 2011;90:521–526. doi: 10.1016/j.ejcb.2010.12.002. PubMed DOI

Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA. Studies of human plate alpha-granule release in vivo. Blood. 1981;58:607–618. PubMed

Gerotziafas GT, Elalamy I, Lecrubier C, Lebrazi J, Mirshahi M, Potevin F, Lecompte T, Samama MM. The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 2001;12:511–520. doi: 10.1097/00001721-200110000-00002. PubMed DOI

Piepkorn MW. Dansyl (5-dimethylaminonaphthalene-1-sulphonyl)-heparin binds antithrombin III and platelet factor 4 at separate sites. Biochem J. 1981;196:649–651. PubMed PMC

Dumenco LL, Everson B, Culp LA, Ratnoff OD. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4. J Lab Clin Med. 1988;112:394–400. PubMed

Yang L, Rezaie AR. Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors. Thromb Haemost. 2007;97:899–906. PubMed

Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, Lentz SR. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood. 2003;102:146–151. doi: 10.1182/blood-2002-11-3529. PubMed DOI

Han ZC, Bellucci S, Walz A, Baggiolini M, Caen JP. Negative regulation of human megakaryocytopoiesis by human platelet factor 4 (PF4) and connective tissue-activating peptide (CTAP-III) Int J Cell Cloning. 1990;8:253–259. doi: 10.1002/stem.5530080409. PubMed DOI

Han ZC, Sensébe L, Abgrall JF, Brière J. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood. 1990;75:1234–1239. PubMed

Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood. 2007;110:1153–1160. doi: 10.1182/blood-2007-01-067116. PubMed DOI PMC

Lambert MP, Wang Y, Bdeir KH, Nguyen Y, Kowalska MA, Poncz M. Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. Blood. 2009;114:2290–2298. doi: 10.1182/blood-2009-04-216473. PubMed DOI PMC

Lambert MP, Xiao L, Nguyen Y, Kowalska MA, Poncz M. The role of platelet factor 4 in radiation-induced thrombocytopenia. Int J Radiat Oncol Biol Phys. 2011;80:1533–1540. doi: 10.1016/j.ijrobp.2011.03.039. PubMed DOI PMC

Lecomte-Raclet L, Alemany M, Sequeira-Le Grand A, Amiral J, Quentin G, Vissac AM, Caen JP, Han ZC. New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides. Blood. 1998;91:2772–2780. PubMed

Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood. 2003;101:4687–4694. doi: 10.1182/blood-2002-08-2363. PubMed DOI

Castor CW, Miller JW, Walz DA. Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor. Cell Biol. 1983;80:765–769. PubMed PMC

El-Gedaily A, Schoedon G, Schneemann M, Schaffner A. Constitutive and regulated expression of platelet basic protein in human monocytes. J Leukoc Biol. 2004;75:495–503. PubMed

Lida N, Haisa M, Igarashi A, Pencev D, Grotendorst GR. Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides. FASEB J. 1996;10:1336–1345. PubMed

Deutsch V, Bitan M, Friedmann Y, Eldor A, Vlodavsky I. Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. Br J Haematol. 2000;111:1180–1189. doi: 10.1046/j.1365-2141.2000.02476.x. PubMed DOI

Resmi KR, Krishnan LK. Protease action and generation of beta-thromboglobulin-like protein followed by platelet activation. Thromb Res. 2002;106:229–236. doi: 10.1016/S0049-3848(02)00135-4. PubMed DOI

Schiemann F, Grimm TA, Hoch J, Gross R, Lindner B, Petersen F, Bulfone-Paus S, Brandt E. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood. 2006;107:2234–2242. doi: 10.1182/blood-2005-06-2424. PubMed DOI

Walz A, Baggioloni M. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med. 1990;171:449–454. doi: 10.1084/jem.171.2.449. PubMed DOI PMC

Walz A, Dewald B, von Tscharner V, Baggiolini M. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med. 1989;170:1745–1750. doi: 10.1084/jem.170.5.1745. PubMed DOI PMC

Castor CW, Ritchie JC, Williams CH Jr, Scott ME, Whitney SL, Myers SL, Sloan TB, Anderson BE. Connective tissue activation. XIV. Composition and actions of a human platelet autacoid mediator. Arthritis Rheum. 1979;22:260–272. doi: 10.1002/art.1780220308. PubMed DOI

Ragsdale CG, Castor CW, Roberts DJ, Swartz KH. Connective tissue activating peptide III. Induction of synthesis and secretion of plasminogen activator by synovial fibroblasts. Arthritis Rheum. 1984;27:663–667. doi: 10.1002/art.1780270609. PubMed DOI

Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD. The beta-thromboglobulins and platelet factor 4: blood platelet derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol. 2000;67:471–478. PubMed

Proudfoot AE, Peitsch MC, Power CA, Allet B, Mermod JJ, Bacon K, Wells TN. Structure and bioactivity of recombinant human CTAP-III and NAP-2. J Protein Chem. 1997;16:37–49. doi: 10.1023/A:1026390811336. PubMed DOI

Tai PK, Liao JF, Hossler PA, Castor CW, Carter-Su C. Regulation of glucose transporters by connective tissue activating peptide-III isoforms. J Biol Chem. 1992;267:19579–19586. PubMed

Stoeckelhuber M, Dobner P, Baumgärtner P, Ehlert J, Brandt E, Mentele R, Adam D, Engelmann B. Stimulation of cellular sphingomyelin import by the chemokine connective tissue-activating peptide III. J Biol Chem. 2000;275:37365–37372. doi: 10.1074/jbc.M003709200. PubMed DOI

Hoogewerf AJ, Leone JW, Reardon IM, Howe WJ, Asa D, Heinrikson RL, Ledbetter SR. CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heaparan sulfate-degrading enzymes. J Biol Chem. 1995;7:3268–3277. PubMed

Pandya NM, Dhalla NS, Santani DD. Angiogenesis—a new target for future therapy. Vascul Pharmacol. 2006;44:265–274. doi: 10.1016/j.vph.2006.01.005. PubMed DOI

Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA. 1968;61:46–52. doi: 10.1073/pnas.61.1.46. PubMed DOI PMC

Karpatkin S, Ambrogio C, Pearlstein E. The role of tumor-induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis. Prog Clin Biol Res. 1988;283:585–606. PubMed

Pinedo HM, Verheul HM, D’Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet. 1998;352:1775–1777. doi: 10.1016/S0140-6736(98)05095-8. PubMed DOI

Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123–134. doi: 10.1038/nrc3004. PubMed DOI PMC

Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate α-granules and differentially released. Blood. 2008;111:1227–1233. PubMed PMC

Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor-4 modulates fibroblast growth factor 2 (FGF2) activity and inhibits FGF2 dimerization. Blood. 1998;91:3289–3299. PubMed

Gengrinowitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem. 1995;270:15059–15065. doi: 10.1074/jbc.270.25.15059. PubMed DOI

Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem. 2005;280:4948–4958. PubMed

Jones SA, Dewald B, Clark-Lewis I, Baggiolini M. Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. J Biol Chem. 1997;272:16166–16169. doi: 10.1074/jbc.272.26.16166. PubMed DOI

Ehlert JE, Ludwig A, Grimm GA, Lindner B, Flad HD, Brandt E. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein. Blood. 2000;96:2965–2972. PubMed

Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhances endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170:3369–3376. PubMed

Tang Z, Yu M, Miller F, Berk RS, Tromp G, Kosir MA. Increased invasion through basement membrane by CXCL7-transfected breast cells. Am J Surg. 2008;196:690–696. doi: 10.1016/j.amjsurg.2008.08.001. PubMed DOI

Castor CW, Whitney SL. Connective tissue activation. XIII. Stimulation of sulfated glycosaminoglycans synthesis in human connective tissue cells by peptide mediators from lymphocytes and platelets. J Lab Clin Med. 1978;91:811–821. PubMed

Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, Weber C. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res. 2007;100:590–597. doi: 10.1161/01.RES.0000259043.42571.68. PubMed DOI

Grupta SK, Singh JP. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol. 1994;127:1121–1127. doi: 10.1083/jcb.127.4.1121. PubMed DOI PMC

Yang L, Du J, Hou J, Jiang H, Zou J. Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. BMC Cancer. 2011;11:s261. doi: 10.1186/1471-2407-11-261. PubMed DOI PMC

Jouan V, Canron X, Alemany M, Caen JP, Quentin G, Plouet J, Bikfalvi A. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood. 1999;94:984–993. PubMed

Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990;247:77–79. doi: 10.1126/science.1688470. PubMed DOI

Chadderton NS, Stringer SE. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Int J Biochem Cell Biol. 2003;35:1052–1055. doi: 10.1016/S1357-2725(02)00299-6. PubMed DOI

Lozano RM, Redondo-Horcajo M, Jiménez MÁ, Zilberberg L, Cuevas P, Bikfalvi A, Rico M, Giménez-Gallego G. Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic aktivity. J Biol Chem. 2001;276:35723–35734. doi: 10.1074/jbc.M101565200. PubMed DOI

Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003;197:1537–1549. doi: 10.1084/jem.20021897. PubMed DOI PMC

Struyf S, Sologni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood. 2011;117:480–488. doi: 10.1182/blood-2009-11-253591. PubMed DOI PMC

Woller G, Brandt E, Mittelstädt J, Rybakowski C, Petersen F. Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. J Leukoc Biol. 2008;83:936–945. doi: 10.1189/jlb.0907592. PubMed DOI

Vandercappellen J, Van Damme J, Struyf S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 2011;22:1–18. doi: 10.1016/j.cytogfr.2010.10.011. PubMed DOI

Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst. 1990;82:848–853. doi: 10.1093/jnci/82.10.848. PubMed DOI

Kolber DL, Knisely TL, Malone TE. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst. 1995;15:304–309. PubMed

Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997;3:437–442. doi: 10.1038/nm0497-437. PubMed DOI

Yamaguchi K, Ogawa K, Katsube T, Shimao K, Konno S, Shimakawa T, Yoshimatsu K, Naritaka Y, Yagawa H, Hirose K. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res. 2005;25:847–852. PubMed

Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 2008;27:31–40. doi: 10.1007/s10555-007-9108-5. PubMed DOI

Petersen F, Bock LA, Flad HD, Brandt E. Chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol. 1998;161:4347–4355. PubMed

Petersen F, Bock L, Flad HD, Brandt E. Platelet factor 4-induced neutrophil-endothelial cell interaction: involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Blood. 1999;94:4020–4028. PubMed

Han ZC, Lu M, Li J, Defard M, Boval B, Schlegel N, Caen JP. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood. 1997;89:2328–2335. PubMed

Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci USA. 1993;90:3574–3577. doi: 10.1073/pnas.90.8.3574. PubMed DOI PMC

von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood. 2005;105:924–930. PubMed

Pervushina O, Scheuerer B, Reiling N, Behnke L, Schröder JM, Kasper B, Brandt E. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J Immunol. 2004;173:2060–2067. PubMed

Scheuerer B, Ernst M, Dürrbaum-Landmann I, Fleischer J, Grage-Griebenow E. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood. 2000;95:1158–1166. PubMed

Fricke I, Mitchell D, Petersen F, Böhle A, Bulfone-Paus S, Brandau S. Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigenpresenting cells. FASEB J. 2004;18:1588–1590. PubMed

Hayashi N, Chihara J, Kobayashi Y, Kakazu T, Kurachi D, Yamamoto T, Nakajima S. Effect of platelet-activating factor and platelet factor 4 on eosinophil adhesion. Int Arch Allergy Immunol. 1994;104(Suppl 1):57–59. PubMed

Brindley LL, Sweet JM, Goetzl EJ. Stimulation of histamine release from human basophils by human platelet factor 4. J Clin Incest. 1983;72:1218–1223. doi: 10.1172/JCI111077. PubMed DOI PMC

Marti F, Bertran E, Llucià M, Villén E, Peiró M, Garcia J, Rueda F. Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. J Leukoc Biol. 2002;72:590–597. PubMed

Fleischer J, Grage-Griebenow E, Kasper B, Heine H, Ernst M, Brandt E, Flad HD, Petersen F. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol. 2002;169:770–777. PubMed

Powell JA Jr, Mousa SA. Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis. J Cell Biochem. 2007;102:412–420. doi: 10.1002/jcb.21302. PubMed DOI

Osselaer NV, Damme JV, Rampart M, Herman AG. Increased microvascular permeability in vivo in response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin. Am J Pathol. 1991;13:23–27. PubMed PMC

Malkowski MG, Lazar JB, Johnson PH, Edwards BF. The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence. J Mol Biol. 1997;226:367–380. PubMed

Belman N, Bonnem EM, Harvey HA, Lipton A. Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest New Drugs. 1996;14:387–389. PubMed

Kahn J, Ruiz R, Kerschmann R, Berger T, Ma R, Coleman R, Alford BL. A phase 1/2 study of recombinant plateler factor 4 (rPF4) in patients with AIDS related Kaposi’s sarcoma (KS) [abstract] Proc Am Soc Clin Oncol. 1993;12:s50.

Northfelt DW, Robles R, Lang W, Wagner B, Kahn J, Bonnem E. Phase I/II study of intravenous (IV) recombinant platelet factor 4 (rPF4) in AIDS-related Kaposi‘s sarcoma (AIDS-KS) [abstract] Proc Am Soc Clin Oncol. 1995;14:s288.

Hersh EM, Wiggins CE, Crook LI, Bonem EM. Phase I study of recombinant platelet factor 4 (rPF4) in patients with metastatic melanoma and renal cell carcinoma [abstract] Proc Am Soc Clin Oncol. 1995;14:s488.

Dinapoli RP, Buckner JC, Rydberg CH, Mullan BP, Davis DH. Phase I-II study of localized injection of recombinant platelet factor 4 (rPF4) in patients (pts) with recurrent high-grade glioma [abstract] Proc Am Soc Clin Oncol. 1995.

Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A, Naumov GN, Bender E, Almog N, Italiano JE Jr, Folkman J, Klement GL. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2008;111:1201–1207. PubMed

Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, D‘Amato RJ, Klement GL, Folkman J. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15:265–273. doi: 10.1007/s10456-012-9259-z. PubMed DOI

Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, McWilliams A, Man SF, Lam S. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol. 2009;27:2787–2792. doi: 10.1200/JCO.2008.19.4233. PubMed DOI PMC

Lee G, Gardner BK, Elashoff DA, Purcell CM, Sandha HS, Mao JT, Krysan K, Lee JM, Dubinett SM. Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients. Am J Transl Res. 2011;3:226–233. PubMed PMC

Grisaru D, Vlodavsky I, Prus D, Levavi H, Lessing JB, Eldor A, Friedmann Y. Connective tissue activating peptide III expression disappears progressively with increased dysplasia in human cervical epithelium. Gynecol Oncol. 2000;79:23–27. doi: 10.1006/gyno.2000.5915. PubMed DOI

Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment